Van Buren II, G., Ramanathan, R.K., Krasinskas, A.M., Smith, R.P., Abood, G.J., Bahary, N., et al. (2013) Phase II Study of Induction Fixed-Dose Rate Gemcitabine and Bevacizumab Followed by 30 Gy Radiotherapy as Preoperative Treatment for Potentially Resectable Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 20, 3787-3793.
http://dx.doi.org/10.1245/s10434-013-3161-9

has been cited by the following article:

• TITLE: Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer

  AUTHORS: Susan Tsai, Kathleen K. Christians, Ben George, Paul Ritch, Kiyoko Oshima, Parag Tolat, Ashley Krepline, Beth A. Erickson, Douglas B. Evans

  KEYWORDS: Pancreas Cancer, Neoadjuvant Therapy, Review

  JOURNAL NAME: Journal of Cancer Therapy, Vol.7 No.1, January 21, 2016

  ABSTRACT: The majority of patients with localized pancreatic cancer (PC) who undergo surgery followed by adjuvant therapy will develop metastatic disease, suggesting that surgery alone is not sufficient for cure and micrometastases are present even when are not clinically detected. As such, the delivery of early systemic therapy may be a rational alternative to a surgery-first approach, in an effort to provide oncologic therapies which are commensurate with the disease stage, and improve surgical selection. This review details the rationale for a neoadjuvant approach to localized PC and provides specific recommendations for both pretreatment staging and treatment sequencing for patients with resectable and borderline resectable PC.